VeraLight's Perfect Storm in Diabetes Screening

In January 2005, the CMS added diabetes screening to its select handful of reimbursed screening tests, paving the way for VeraLight Inc., a new company developing a non-invasive alternative to the current standard diabetes screening test, fasting blood glucose.

In a US health care system based largely on fixing problems rather than preventing them, looking for diseases in asymptomatic populations has always been controversial. Concerns around cost-effectiveness and the need to definitively link therapies to improved outcomes have prevented the adoption of screening paradigms for more than a handful of conditions. Diabetes became one of them in January 2005, when CMS added it to its list of reimbursed tests, paving the way for VeraLight Inc. , a new company developing a noninvasive alternative to fasting blood glucose, which is the current standard diabetes screening test.

In fact, a number of factors have come together recently, creating the perfect storm for VeraLight’s diabetes screening technology, says...

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.